Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke

Stroke

Volumn 40, Issue 5, 2009, Pages 1729-1737

  Meier, Niklaus ^a   Nedeltchev, Krassen ^a   Brekenfeld, Caspar ^a   Galimanis, Aekaterini ^a   Fischer, Urs ^a   Findling, Oliver ^a   Remonda, Luca ^a   Schroth, Gerhard ^a   Mattle, Heinrich P ^a   Arnold, Marcel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cerebral ischemia; Cholesterol; Hemorrhage; Statins; Thrombolysis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; FIBRINOLYTIC AGENT;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ACUTE DISEASE; BLOOD; BRAIN ANGIOGRAPHY; BRAIN ISCHEMIA; CLASSIFICATION; FIBRINOLYTIC THERAPY; FOLLOW UP; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; RISK FACTOR; STROKE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBRAL HEMORRHAGE; CHOLESTEROL; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549120604     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.532473     Document Type: Article

References (53)

1. Brekenfeld C, Remonda L, Nedeltchev K, v Bredow F, Ozdoba C, Wiest R, Arnold M, Mattle HP, Schroth G. Endovascular neuroradiological treatment of acute ischemic stroke: techniques and results in 350 patients. Neurol Res. 2005;27(suppl 1):S29-35.
2. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, Gobin YP, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Vinuela F. Predictors of hemorrhagic transformation in patients receiving intra-arte-rial thrombolysis. Stroke. 2002;33:717-724.
3. Tountopoulou A, Ahl B, Weissenborn K, Becker H, Goetz F. Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation. Neuroradiology. 2008;50: 75-83.
4. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001; 57:1603-1610.
5. Suarez JI, Sunshine JL, Tarr R, Zaidat O, Selman WR, Kernich C, Landis DM. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ische-mic stroke. Stroke. 1999;30:2094-2100.
6. Brekenfeld C, Remonda L, Nedeltchev K, Arnold M, Mattle HP, Fischer U, Kappeler L, Schroth G. Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry. 2007;78: 280-285.
7. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-2909.
8. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
10. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68: 737-742.
11. Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, Sturzenegger M, Mattle HP. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke. 2002; 33:1828-1833.
12. Arnold M, Nedeltchev K, Schroth G, Baumgartner RW, Remonda L, Loher TJ, Stepper F, Sturzenegger M, Schuknecht B, Mattle HP. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry. 2004;75:857-862.
13. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20: 864-870.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med. 1985;312:932-936.
16. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
17. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
18. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombol-ysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
19. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
20. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, Molina CA, Montaner J. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007;38: 1076-1078.
21. Montaner J. Cholesterol measured before stroke thrombolysis is not associated with tissue-plasminogen activator-related hemorrhagic transformation. Stroke. 2008;39:e6.
22. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis. 2007;24:170-182.
23. Reiss AB, Wirkowski E. Role of HMG-CoA reductase inhibitors in neurological disorders: progress to date. Drugs. 2007;67:2111-2120.
24. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21:1712-1719.
25. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248-2253.
26. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251.
27. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196-201.
28. Szapary L, Horvath B, Marton Z, Alexy T, Kesmarky G, Habon T, Szots M, Koltai K, Juricskay I, Czopf J, Toth K. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyper-lipidaemia. CNS Drugs. 2004;18:165-172.
29. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 1999;95: 229-234.
30. Ural AU, Yilmaz MI, Avcu F, Yalcin A. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. Int J Hematol. 2002;76:279-283.
31. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgerany-lation and rho proteins. Circ Res. 1998;83:683-690.
32. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and rho proteins. J Am Soc Nephrol. 1998;9:1377-1388.
33. Aarons CB, Cohen PA, Gower A, Reed KL, Leeman SE, Stucchi AF, Becker JM. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg. 2007;245:176-184.
34. Lai WT, Lee KT, Chu CS, Voon WC, Yen HW, Tsai LY, Sheu SH. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol. 2005;98:459-464.
35. Fogari R, Derosa G, Lazzari P, Zoppi A, Fogari E, Rinaldi A, Mugellini A. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens. 2004;17:823-827.
36. Orem C, Uydu HA, Yilmaz R, Gokce M, Baykan M, Eminagaoglu S, Orem A. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. Jpn Heart J. 2004;45:977-987.
37. Haslinger B, Goedde MF, Toet KH, Kooistra T. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int. 2002;62:1611-1619.
38. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002;135:284-292.
39. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibri-nolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4:1029-1036.
40. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation. 2001;103:387-392.
41. Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebro-vascular events. J Neurol Sci. 2004;221:5-10.
42. Yoon SS, Dambrosia J, Chalela J, Ezzeddine M, Warach S, Haymore J, Davis L, Baird AE. Rising statin use and effect on ischemic stroke outcome. BMC Med. 2004;2:4.
43. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke. 2008; 39:1779-1785.
44. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia MD, Molina-Porcel L, Diaz-Manera J, Marti-Vilalta JL. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35:1117-1121.
45. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology. 2005;65:253-258.
46. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006;37:2640-2643.
47. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Davalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904-910.
48. Lee SR, Guo SZ, Scannevin RH, Magliaro BC, Rhodes KJ, Wang X, Lo EH. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett. 2007;417:1-5.
49. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
50. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006; 66:1550-1555.
51. Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke. 2006;37: 1910-1912.
52. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Jones J, Boden-Albala B, Paik MC, Sacco RL. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139:391-399.
53. Aull S, Lalouschek W, Schnider P, Sinzinger H, Uhl F, Zeiler K. Dynamic changes of plasma lipids and lipoproteins in patients after transient ischemic attack or minor stroke. Am J Med. 1996;101:291-298.